BioSpace News Archive

iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, announced that management will participate in two upcoming virtual investor conferences in September.

HTG Molecular Diagnostics, Inc., a diagnostic company whose mission is to advance precision medicine, announced John Lubniewski, President and CEO of HTG, will present virtually at the H.C. Wainwright 22nd Annual Global Investment Conference and at the Cantor Fitzgerald Global Healthcare Conference.

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, announced that it will participate in the following investor conferences:

Abeona Therapeutics Inc., a fully-integrated leader in gene and cell therapy, announced that the Company will participate in the following upcoming investor conferences.

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, announced that Frank Bedu-Addo, CEO of PDS Biotech, will present virtually at the H.C. Wainwright & Co.

Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, announced the appointment of Rachel Humphrey, M.D., as Chief Medical Officer.

Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced that it will participate at the following virtual investor conference

Adamas Pharmaceuticals, Inc., a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, announced that Neil F. McFarlane, the Company’s Chief Executive Officer, is scheduled to present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15th at 12:30 pm Eastern Time.

Lexicon Pharmaceuticals, Inc. announced the completion of the sale of Lexicon’s rights, title and interest in XERMELO® to TerSera Therapeutics LLC.

TTI-622 (SIRPa-IgG4 Fc) completed 8 mg/kg safety assessment in the ongoing dose escalation study in relapsed/refractory lymphoma; now escalating to 12 mg/kg dose level.